Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke
Launched by UNIVERSITY OF VIRGINIA · Mar 2, 2024
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a genetic test can help doctors choose the best blood-thinning medication for patients who have had an ischemic stroke, which is caused by a blood clot in the brain. After such a stroke, patients typically receive two types of blood thinners to prevent another stroke. However, one of these medications, called clopidogrel, may not work well for some people due to differences in their DNA. The trial aims to see if testing for these genetic differences in the hospital can help doctors prescribe the right medication, potentially lowering the risk of another stroke.
To participate in this study, individuals must be at least 18 years old and have symptoms of an acute ischemic stroke or a related condition. They need to be evaluated within 24 hours of their symptoms starting, or within 24-96 hours if they are already on blood thinners. Participants will undergo a simple genetic test that looks for specific variations in their DNA. The results will guide doctors in prescribing the most effective blood thinner for their situation. It’s important to note that this study is currently recruiting participants and aims to find the best ways to implement this genetic testing in hospitals.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and women at least 18 years of age
- • Presenting with symptoms of acute ischemic stroke or transient ischemic attack and without contraindications to dual antiplatelet therapy at time of clinical research coordinator screening
- • Presenting within 24 of symptom onset; or, within 24-96 hours of symptom onset IF planned to receive or already on dual antiplatelet therapy
- Exclusion Criteria:
- • Receiving therapeutic anticoagulation or clear indication for initiation of anticoagulation after event (e.g., known atrial fibrillation)
- • History of allogeneic bone marrow transplant
- • History of liver transplant
- • Subject who is unable to consent and does not have a surrogate available to consent on their behalf
About University Of Virginia
The University of Virginia (UVA) is a prestigious academic institution renowned for its commitment to advancing medical research and improving patient care through innovative clinical trials. With a focus on interdisciplinary collaboration, UVA leverages its extensive resources and expertise in various fields, including medicine, engineering, and public health, to drive cutting-edge studies that address pressing health challenges. The university's clinical trial programs aim to translate scientific discoveries into effective treatments, ensuring the highest standards of ethical practice and participant safety. Through its strong emphasis on community engagement and education, UVA fosters a culture of research that not only contributes to the scientific community but also enhances the well-being of the populations it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Charlottesville, Virginia, United States
Patients applied
Trial Officials
Rachael M Stone, PharmD
Principal Investigator
University of Virginia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported